Evaluation of the XIENCE PRIME LL and XIENCE Nano Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms EXPERT CTO
- Sponsors Abbott Laboratories
- 07 Jun 2017 Biomarkers information updated
- 31 Mar 2014 Results after 1-year follow-up presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 18 Mar 2013 Planned End Date changed from 1 May 2017 to 1 Feb 2018 as reported by ClinialTrials.gov.